United States Cell & Gene Therapy - Focused Insights 2023-2028: Approval of Over 20 Cell Therapy and 31 Gene Therapy Launches in the Pipeline for 2024
23 Jun 2023
Gene TherapyPhase 2Cell TherapyImmunotherapy
DUBLIN, June 23, 2023 /PRNewswire/ -- The "US Cell & Gene Therapy Market - Focused Insights 2023-2028" report has been added to
ResearchAndMarkets.com's offering.
This report offers market size & forecast data for the cell & gene therapy market in the US. The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies. Cell therapies sourced from mesenchymal stem cells, cell-based immune modulation therapies, and cell/tissue-based products derived from patients' blood are also covered in the report. Tissue-engineered products and tissue grafts/scaffolds with synthetic mechanical structures are excluded from the report's scope. This report provides a comprehensive and current market scenario of the US cell & gene therapy market, including the US cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends.
The study considers a detailed scenario of the present cell and gene therapy market and its market dynamics for 2023-2028 in the US. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.
In recent years, growth in the cell and gene therapy market has fueled some high-profile mergers and acquisitions, including bluebird bio/BioMarin, Bristol-Myers Squibb/Celgene/Juno Therapeutics, Gilead Sciences/Kite, Novartis/AveXis and the CDMO CELLforCURE, Roche/Spark Therapeutics, and Smith & Nephew/Osiris Therapeutics. Over 20 cell therapy launches and as many as 31 gene therapy launches - including more than 29 Adeno-associated viruses (AAV) therapies - are projected to be approved by 2024.
KEY HIGHLIGHTS OF THE REPORT
The US cell and gene therapy market was valued at $3.22 billion in 2022 and is projected to reach $25.58 billion in 2028, with a compound annual growth rate (CAGR) of 41.25%, during the study period.
Drug developers are prioritizing developing and commercializing CAR-T cell-based gene therapies. Globally, more than 1,000 clinical trials are being conducted on CAR T-cell therapies, of which at least 500 clinical trials are for cancer alone. Kymriah (Novartis), Yescarta (Gilead Sciences), Tecartus (Gilead Sciences), Breyanzi (Bristol Myers Squibb), Abecma (Bristol Myers Squibb), and Carvykti (Janssen Biotech / Legend Biotech) are the commercial CAR-T therapies available in the market.
In 2022, the US was the fastest-growing market with a high market share in North America. The market is driven by an increased target patient population, regulatory body support, and higher access to healthcare due to well-established healthcare infrastructure.
The Food and Drug Administration (FDA) has approved over twenty cell and gene therapy drugs. Still, the new product pipeline has approximately 365 investigational therapies, with more than half of these in Phase 2 clinical trials. Oncology and rare diseases remain the top areas targeted by gene therapies from preclinical through pre-registration.
Approximately 1,604 clinical trials are under investigation for various cell and gene therapies in the US. This increase could be because of increased funding for cell and gene therapy. The industry-sponsored trials are continued to dominate with a share of 51.81%.
Novartis, Gilead Sciences, Spark Therapeutics, Amgen, Orchard Therapeutics, Bristol-Myers Squibb, BioMarin, PTC TherapeuticsPTC Therapeutics, and Organogenesis are the leading players in the US cell and gene therapy market. The market offers tremendous growth opportunities for existing and future/emerging players because of a large pool of target patient populations with chronic diseases such as cancer, genetic and rare diseases, and other complex disorders.
Key Topics Covered:
CHAPTER - 1: Cell & Gene Therapy Market Overview
Executive Summary
Introduction
Key Findings
Key Developments
CHAPTER - 2: Cell & Gene Therapy Market Segmentation Data
US: Projected Revenue of Cell & Gene Therapy (2022-2028; $Billions)
Product type
Application type
End-user type
CHAPTER - 3: Cell & Gene Therapy Prospects & Opportunities
Cell & Gene Therapy Market Drivers
Cell & Gene Therapy Market Trends
Cell & Gene Therapy Market Constraints
CHAPTER - 4: Cell & Gene Therapy Industry Overview
Cell & Gene Therapy - Marketed Drugs Overview
Cell & Gene Therapy - Pipeline Drugs Overview
Cell & Gene Therapy - Competitive Landscape
Cell & Gene Therapy - Key Players
Cell & Gene Therapy - Key Company Profiles
Cell & Gene Therapy - Mergers & Acquisitions
Cell & Gene Therapy - Key Strategic Recommendations
CHAPTER - 5: Pricing and Reimbursement Scenario
Pricing, Reimbursement and Market Access
Contract Manufacturing Organizations (CMOs)
CHAPTER - 6: Appendix
Research Methodology
Abbreviations
Companies Mentioned
bluebird bio
UniQure
Organogenesis
Mallinckrodt
Enzyvant
4DMT
Castel Creek Biosciences
Cellectis
Gamida Cell
Adaptimmune
For more information about this report visit https://www.researchandmarkets.com/r/ykk5vf
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.